Abstract:Multiple myeloma (MM) is a highly heterogeneous hematological malignancy that is currently incurable. Individualized therapeutic approaches based on accurate risk assessment are essential for improving the prognosis of MM patients. Nevertheless, current prognostic models for MM exhibit certain limitations and prognosis heterogeneity still an unresolved issue. Recent studies have highlighted the pivotal involvement of mitochondrial autophagy in the development and drug sensitivity of MM. This study seeks to conduct an integrative analysis of the prognostic significance and immune microenvironment of mitophagy-related signature in MM, with the aim of constructing a novel predictive risk model. GSE4581 and GSE47552 datasets were acquired from the Gene Expression Omnibus database. MM-differentially expressed genes (DEGs) were identified by limma between MM samples and normal samples in GSE47552. Mitophagy key module genes were obtained by weighted gene co-expression network analysis in the Cancer Genome Atlas (TCGA)-MM dataset. Mitophagy DEGs were identified by the overlap genes between MM-DEGs and mitophagy key module genes. Prognostic genes were selected through univariate Cox regression and least absolute shrinkage and selection operator (LASSO) analysis, and a risk model was subsequently constructed based on these prognostic genes. Subsequently, the MM samples were stratified into high- and low-risk groups based on their median risk scores. The validity of the risk model was further evaluated using the GSE4581 dataset. Moreover, a nomogram was developed using the independent prognostic factors identified from the risk score and various clinical indicators. Additionally, analyses were conducted on immune infiltration, immune scores, immune checkpoint, and chemotherapy drug sensitivity. The 17 mitophagy DEGs were obtained by intersection of 803 MM-DEGs and 1084 mitophagy key module genes. Five prognostic genes (CDC6, PRIM1, SNRPB, TOP2A, and ZNF486) were selected via LASSO and univariate cox regression analyses. The predictive performance of the risk model, which was constructed based on the five prognostic genes, demonstrated favorable results in both TCGA-MM and GSE4581 datasets as indicated by the receiver operating characteristic (ROC) curves. In addition, calibration curve, ROC curve, and decision curve analysis curve corroborated that the nomogram exhibited superior predictive accuracy for MM. Furthermore, immune analysis results indicated a significant difference in stromal scores of two risk groups categorized on median risk scores. And four immune checkpoints (CD274, CTLA4, LAG3, and PDCD1LG2) showed significant differences in different risk groups. The analysis of chemotherapy drug sensitivity revealed that etoposide and doxorubicin, which target TOP2A , exhibited superior treatment outcomes in the high-risk group. A novel prognostic model for MM was developed and validated, demonstrating significant potential in predicting patient outcomes and providing valuable guidance for personalized immunotherapy counseling.

Prognostic significance of β2-microglobulin decline index in multiple myeloma

[Influence of Prognostic Nutritional Index and Controlling Nutritional Status on the Prognosis of Patients with Multiple Myeloma].

The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients

Treatment and Prognostic Factors for Survival in Newly Diagnosed Multiple Myeloma Patients with Bortezomib and Dexamethasone Regimen: a Single Chinese Center Retrospective Study

Clinical Characteristics and Prognosis of Multiple Myeloma Patients Treated with Hemodialysis: a Single Center Study

Integrative Analysis of the Prognostic Value and Immune Microenvironment of Mitophagy-Related Signature for Multiple Myeloma.

[Clinical analysis of newly diagnosed multiple myeloma patients with renal dysfunction].

MiRNAs with Prognostic Significance in Multiple Myeloma

Identifying the prognostic significance of mitophagy-associated genes in multiple myeloma: a novel risk model construction

Prognostic Value of Immune Status Changes after Chemotherapy in Patients with Newly Diagnosed Multiple Myeloma

A novel glycolysis-related gene signature for predicting the prognosis of multiple myeloma

[Prognostic Significance of CD27 and CD56 on Newly Diagnosed MM Patients Treated with Bortezomib].

MiRNAs with prognostic significance in multiple myeloma: A systemic review and meta-analysis.

Revisiting beta‐2 microglobulin as a prognostic marker in diffuse large B‐cell lymphoma

An emerging prognosis prediction model for multiple myeloma: Hypoxia-immune related microenvironmental gene signature

Developing mRNA signatures as a novel prognostic biomarker predicting high risk multiple myeloma

Optimal cut-off values and diagnostic significance of clinical laboratory indicators in newly diagnosed multiple myeloma

Integration of Clinical Features and Sociodemographic Factors: a Simplified Prognostic Model for Patients with Multiple Myeloma Based on a Double-Center Retrospective Analysis.

Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma

A New Prognostic Scoring System for Newly Diagnosed Multiple Myeloma in the Era of New Drugs

Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis